NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its first-quarter revenues swelled 12 percent year over year, or 9 percent on a currency-neutral basis, driven largely by a 10 percent spike in its diagnostics sales, while revenues from the BD Biosciences segment were flat.
The Franklin Lakes, NJ-based maker of diagnostics, medical products, and life science research tools reported revenues of $1.9 billion for the three-month period ended December 31, up from revenues of $1.7 billion in the first quarter of 2009.
The BD Biosciences business segment had revenues of $302.7 million for the quarter, and was nearly unchanged from its revenues of $302.5 million for Q1 2009. That segment's Cell Analysis revenues were up 1 percent at $231.3 million compared with $229.5 million, and its Discovery Labware business fell 2 percent to $71.3 million from $73 million in the year-ago period
The BD Diagnostics segment had revenues of $595.5 million, a 10 percent increase from revenues of $540.2 million for the second quarter of 2009. The BD Diagnostics segment's Pre-analytical Systems business saw in increase of 8 percent to $300.2 million from $278.2 million. The Diagnostics Systems business rose to $295.3 million from $262 million, an increase of 13 percent.
BD's net income for Q1 was $316.4 million, or $1.30 per share, from $312.1 million, or $1.26 per share, for Q1 2009. Its R&D expenses increased roughly 3 percent to $100.3 million from $97.3 million, while its SG&A spending rose 11 percent to $450.9 million from $406 million.
The firm expects to report growth of around 7 percent for full-year 2010, compared with its earlier guidance of around 6 percent.